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Summary 
Major histocompatibility complex  (MHC)  class II combined immunodeficiency (CID),  also 
known as type II bare lymphocyte syndrome, is an autosomal recessive genetic disorder charac- 
terized by the complete lack of expression of MHC class II antigens. The defect results from a 
coordinated lack of transcription of all class II genes.  Cell fusion studies  using many patient- 
and experimentally derived class II-negative cell lines have identified four distinct genetic com- 
plementation groups. In this report, we present genetic evidence that cell lines derived from 
two newly described MHC class II-deficient patients, KER and KEN, represent a fifth com- 
plementation group. In addition, the KER and KEN cell lines display a unique pattern of dys- 
coordinate regulation of their MHC class II genes, which is reflected in a new phenotype of in 
vivo promoter occupancy as revealed by in vivo genomic footprinting.  These data point to a 
new defect that can result in the MHC class II-deficient phenotype. 
M 
HC  class  II  antigens  are  highly  polymorphic  cell 
surface glycoproteins that are intimately involved in 
the generation of the immune response (1).  In the human, 
three isotypes (HLA-DR, -DQ, and -DP) of class II anti- 
gens are encoded by the HLA-D locus on chromosome 6. 
Each isotype consists of an 0~ and [3 chain,  which together 
form  a  heterodimeric  structure  capable  of  binding  ex- 
ogenously derived peptides and presenting them to CD4 + 
Th cells  (2).  The expression of class II molecules is limited 
to APC,  such as B  cells,  macrophages, and dendritic  cells, 
and to thymic epithelial cells, where expression is involved 
in the "education"of naive T  cells before their exportation 
to the periphery (2,  3).  In addition to the constitutive and 
inducible expression on cells of the immune system, class II 
levels  can  also  be  induced  on  otherwise  class  II-negative 
cells by exposure to cytokines such as IFN-~ (2). 
The lack of expression of MHC class II molecules results 
in  an  immunodeficiency  called  MHC  class  II  combined 
immunodeficiency  (CID), 1 or  the  bare  lymphocyte  syn- 
drome. The disease is characterized by the complete lack of 
1Abbreviations used in this paper: B-LCL, B lymphoblastoid  ceil line; CID, 
combined immunodeficiency; CIITA,  class II tram-activator; P,.F-X, 
DNA-binding protein complex. 
constitutive  and  inducible  expression  of class  II  antigens 
(4). Patients with MHC class II CID demonstrate failure to 
thrive,  subsequently  develop  overwhelming bacterial  and 
viral infections, and usually die in childhood unless treated 
with  bone  marrow  transplantation  (4,  5).  The  defect  in 
gene expression is at the level of transcription and affects all 
class II genes coordinately  (6).  Genetic studies  of affected 
fanfilies have shown that the defect does not segregate with 
the MHC  and suggest that the  class I[ structural  genes in 
such patients are intact (7). The defect, rather, appears to be 
due to a malfunctioning trans-acting factor(s), as fusion of a 
class II-negative derivative of the Burkitt's lymphoma Raft 
to a class II-positive murine B lymphoma results in the res- 
toration of expression of human class II antigens (8). More 
extensive cell fusion studies,  using a panel of CID patient 
EBV-transformed B lymphoblastoid cell lines (B-LCL), have 
identified  four  complementation  groups,  suggesting  that 
four separate genetic  lesions  can give rise to  the  class II- 
deficient phenotype  (9-11).  In complementation groups I 
and IV, the lack of class II expression is thought to be due 
to a deficiency in a DNA-binding protein complex (R.F-X) 
that binds to the conserved X box in class II promoters (12, 
13).  A  cDNA for one member of the RF-X family, RF- 
X5, has recently been reported to restore class II expression 
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gene  defective in complementation  group  II, termed  class 
II tram-activator  (CIITA), has recendy been isolated by ex- 
pression cloning and has been shown to be sufficient to restore 
class II antigen expression in all cell lines from this comple- 
mentation group (15). The gene(s) defective in complemen- 
tation group III remains to be identified. 
Recently two new patients with MHC  class II deficiency 
have been identified based on the lack of surface expression 
of class II antigens  on  their peripheral  B  cells and  mono- 
cytes  (16).  Unlike  other  class  II  CID  patients,  these  his- 
toidentical  twin  brothers  have  normal  numbers  of CD4 + 
cells and are able to mount both cellular and humoral im- 
mune responses, presumably because of extremely low lev- 
els of class II antigen expression in certain adherent mono- 
nuclear  cells.  Analysis of the  transcription  of class II genes 
in  EBV-transformed  B-LCL  derived  from  these  patients 
revealed  a  previously  undescribed  dyscoordinate  pattern 
of expression:  whereas  levels  of DRcx,  DQot,  and  DPJ3 
mRNA  were  approximately normal  compared  with  con- 
trols, DRy,  DQI3, and DP~ mRNA  were completely ab- 
sent (17). Taken together,  these results suggested that these 
patients represent a novel phenotype of MHC  class II defi- 
ciency. 
In this study, we have examined the expression of HLA- 
DR  in transient  heterokaryons  formed by fusion between 
the patients' EBV-transformed B-LCL, KEN and KER, and 
cell lines  from each  of the  four established  complementa- 
tion groups.  Our data provide genetic  evidence for a fifth 
complementation  group  of MHC  class II deficiency char- 
acterized by a dyscoordinate expression of the class II genes. 
In addition,  direct examination of the promoter regions of 
the  class  II genes  in  KEN  and  KER  by in  vivo  genomic 
footprinting reveals that this dyscoordinate expression is as- 
sociated with a new pattern of promoter occupancy differ- 
ent  from  those  previously  described  for  class  II-negative 
cell lines. 
Materials and Methods 
Cell Lines.  Experimentally derived class II-negative cell lines 
were  maintained  in  RPMI  1640  medium  supplemented  with 
10% FCS, 10 mM Hepes, 2 mM glutamine, 50 IxM 2-ME, peni- 
cillin  (100 U/ml), and streptomycin (100 I~g/ml). 721.174  (18) is 
an EBV-transformed B-LCL that bears a homozygous deletion of 
the DR,  DQ,  and part of the DP region.  RM3  (19)  is a class 
II-negative  derivative  of the  human  Burkitt  lymphoma  Rail, 
whereas  6.1.6  (20)  is  derived  from the  class II-positive EBV- 
transformed  B-LCL  T5.1.  All  three  cell  lines  are  negative  for 
DR, DQ, and DP expression. 
The  patient-derived  EBV-transformed  B-LCL  KEN,  KER, 
Nacera (21), BLS-1 (22), TF (23), and SJO (24) were maintained 
in RPMI 1640 medium supplemented with 20% FCS along with 
the additives  listed above. EBV-transformed B-LCL derived from 
the mother and father of KER and KEN were grown in the same 
medium. 
Cell Fusion.  For the  preparation of transient  heterokaryons, 
10  6 cells of each type were mixed in a 5-ml centrifuge tube and 
washed three times in serum-free medium. The cells were disag- 
gregated by three passages through an 18-gauge needle and were 
washed once more in serum-free medium. Cell pellets were gen- 
tly dispersed and warmed to  37~  Fusion  was initiated by the 
dropwise  addition  of 0.1  ml  PEG  1500  (50%  wt/vol)  (Boeh- 
ringer-Mannheim Corp., Indianapolis,  IN) over the course of 1 
min. 5 ml of serum-flee medium was then added slowly over a 
5-min period. Cells were rested at room temperature for 5 min, 
pelleted at 250 g for 3 rain, and plated in 5 ml of complete me- 
dium.  After 48 h,  the cells were analyzed for the expression of 
HLA-DR by incubation  with FITC-conjugated anti-HLA-DR 
mAh L243 (Becton Dickinson & Co., San Jose, CA). 
In  Vivo Genomic Footprinting.  Preparation  of in  vitro  and  in 
vivo methylated genomic DNA and piperidine treatment were as 
described (25). Piperidine-treated genomic DNA (5 ~g) was used 
in ligation-mediated PCR as described (26).  Primers specific  for 
the  DR0t,  DR{3,  and  the  DQ{3  promoter coding strands  have 
been described (25, 27). 
RNA Analysis.  Total  cellular  RNA  was  extracted  as  de- 
scribed (28). 20/*g of RNA was electrophoresed on 1.2% agarose 
gels,  blotted to  GeneScreen  (DuPont-NEN,  Boston,  MA),  and 
hybridized  with  radioactive  probes  generated  by  random-hex- 
amer labeling. 
Results 
Complementation Analysis.  To  determine  if the  MHC 
class II-deficient cell lines KER and KEN belong to any of 
the four previously defined CID complementation groups, 
transient  heterokaryons  were  prepared  and  analyzed  48  h 
after fusion for expression of HLA-DR antigens. Cells from 
both  KEN  and  KER  were  fused  to  the  following  EBV- 
transformed B-LCL representing all four known CID com- 
plementation  groups:  Nacera  and BLS-1  (group  1),  RM3 
(group  II), 6.1.6  (group  III), and  TF  (group-IV).  tn addi- 
tion, 721.174,  an experimentally derived EBV-transformed 
B-LCL that lacks the class II structural genes, was used as a 
further  control.  Each fusion  experiment  also  included  fu- 
sions between pairs of cells from groups I, II, III, and IV. 
Results  of multiple  fusion  experiments  are  summarized 
in Table 1. Fusion of KEN to KER yielded no class II-pos- 
itive  heterokaryons,  whereas  fusion  of either  cell  hne  to 
721.174 caused reexpression of HLA-DR. These results sug- 
gest that both the transcribed  (DRot,  DQot,  and DPJ3)  and 
the  nontranscribed  (DR{3,  DQJ3,  and DPet)  class II struc- 
tural  genes  in  KER  and  KEN  are  functionally  intact  and 
that the nontranscribed  genes can be expressed in the pres- 
ence of the appropriate  trans-acdng  factor.  Fusion of KEN 
or KER  to  cell lines  from groups  I,  II, and  IV invariably 
gave rise to heterokaryons that showed expression of HLA- 
DR  and thus clearly demonstrate that both KER and KEN 
do not belong to any of these complementation groups. Al- 
though  the  only  cell  line  in  group  III, 6.1.6,  has  a  small 
percentage  of class  II-positive revertants,  repeated fusions, 
scored  bhndly,  indicated  that  both  KER  and  KEN  can 
complement 6.1.6  and thus do not belong to complemen- 
tation  group  III. Fig.  1 shows the  results from representa- 
tive  fusion  experiments  between  KER  and  721.174,  Na- 
cera (group I), RM3  (group II), and TF  (group IV). Based 
on this analysis, KER and KEN clearly define a new corn- 
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721.174 KEN KER Nacera BLS-1 RM3 6.1.6 TF SJO 
721.174  - 
KEN  +  - 
KER  +  -  - 
Nacera  +  +  + 
BLS-1  +  +  + 
RM3  +  +  + 
6.1.6  +  +  + 
TF  +  +  + 
SJO  +  +  + 
+ 
+  + 
+  + 
+  + 
+  + 
+  -- 
+  + 
+  + 
Transient heterokaryons were formed between  the pairs of cell lines 
listed above and analyzed for HLA-DR expression 48 h after fusion. 
(+) denotes HLA-DR-positive  fusion products; (-) denotes no HLA- 
DR-positive fusion products observed. 
plementation  group of MHC  class II deficiency, which we 
call complementation group V. 
Promoter Occupancy in Group  V CID.  The occupancy of 
the MHC  class II promoters in both class II-positive B  cells 
and class  II-negative CID cells as analyzed by in vivo ge- 
nomic footprinting has revealed two predominant promoter 
phenotypes:  (a) an "occupied" promoter is characterisic  of 
class  II-positive B  lymphoblastoid cells as well as those cell 
lines  that  belong to  complementation  group  II,  and  (b)  a 
"bare"  promoter  is  found in  all  cell  lines  examined  from 
complementation groups I, III, and IV (27). Although the 
patterns of protection of the conserved X1, X2, and Y  ele- 
ments  in  the  proximal  promoters  of the  class  II  genes  of 
CID cell lines can show either an occupied or bare pheno- 
type, all the class  II genes in a given cell type display a co- 
ordinated  pattern  of occupancy reflecting  the  fact that  all 
the class  II genes are either transcriptionally active or inac- 
tive. Given the dyscoordinate expression of  class II mRNAs 
in  KER  and  KEN  (DRot+DR[3 -,  DQct+DQ[3  -,  DPcx- 
DP[3+), we examined the promoters of three class  II genes 
in  these  cells  by  in  vivo  genomic  footprinting.  In  both 
KER  and  KEN,  the  DRot  gene  is  transcribed  at  normal 
levels,  and indeed,  the DRc~ promoter is occupied in both. 
The pattern of protection of the X1, X2, Y, and the DRcx- 
specific  octamer  elements  was  identical  to  that  seen  in  a 
class II-positive EBV-transformed B-LCL derived from the 
mother  of the  patients  (Fig.  2,  /eft). In contrast,  the  pro- 
moter of the nontranscribed DR[3 gene is not protected in 
either KER or KEN (Fig. 2, right). Footprint analysis of the 
DQ[3  promoter,  which  is  nontranscribed  in  KER  and 
KEN,  also revealed the bare  phenotype  (data  not shown). 
These in vivo genomic footprinting studies suggest that in 
group  V  CID,  those  class  II  genes  that  are  actively tran- 
scribed (DRop, DQot, and DP[3) have occupied promoters, 
whereas those genes that are not transcribed  (DR[3, DQ[3, 
and DPo  0  have bare promoters. Thus, in addition to defin- 
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Figure  1.  Reexpression  of  HLA-DR on the surface of  transient hetero- 
karyons formed between group V CID and other class lI-negative cell 
lines. Transient heterokaryons were formed by PEG mediated fusion of 
KEK and 721.174, KER and Nacera, KER and RM3, and KER and TF 
and analyzed 48 h later for expression of surface HLA-DR by immuno- 
fluorescence. Normarski  (left) and  immunofluorescence (right) micro- 
graphs are shown (￿ 
ing a new genetic defect that can lead to MHC class  II de- 
ficiency, cell lines in  complementation  group V  exhibit  a 
novel, mixed in vivo promoter phenotype characterized by 
a  dyscoordinate  pattern  of promoter  occupancy between 
the oc and {3 chain genes of a given HLA-D isotype. 
Transcription of Other Genes in the MHC.  Since  the  cell 
lines KER and KEN displayed a completely new pattem of 
expression of the MHC class II genes, we examined the ex- 
pression of two other class II-related genes whose promot- 
ers  share  some  of the  conserved  elements  common to  all 
class II genes. DMA and DMB, which map within the class 
II region of the MHC  between  the DP and the DQ  loci, 
have been shown to be essential for class II-mediated anti- 
gen presentation  (29). Two CID cell lines,  SJO (group IV) 
and BLS-1  (group I) have recently been found to lack ex- 
pression of both DMA and DMB,  suggesting a  coordinate 
regulation  of the  class  II  structural  genes  and  the  related 
DMA and DMB genes (30).  Northern blot analysis of cel- 
lular  RNA  derived from KER  and KEN  (Fig.  3)  probed 
for DMA and DMB reveal that neither  cell line  expresses 
either  of these  two  transcripts,  whereas  class  II-positive 
EBV-transformed B-LCL derived from the patients' mother Figure 2.  The DR~x but not the DR[3 promoter is occupied in group 
V CID cell lines. In vitro and in vivo methylated genomic DNA was pre- 
pared from KER, KEN, and an EBV-transformed B-LCL derived from 
the patient's mother and analyzed as described in Materials and Methods. 
In vitro methylated DNA is in lanes marked (-); in vivo methylated 
DNA is in lanes marked (+). Regions encompassing  the regulatory ele- 
ments X1, X2, Y, and octamer (oct) are indicated by bars. Residues pro- 
tected in vivo are indicated by arrows. 
and  father  express  normal  amounts  of mRNA  for  both 
DMA and DMB. Interestingly, TAP1 and TAP2, two genes 
also located in the MHC class II locus that are clearly regu- 
lated  differently  than  the  class  II  genes  (31,  32),  are  ex- 
pressed normally in both KEIL and KEN (data not shown). 
Discussion 
The  immunological  profile  and  the  unique  pattern  of 
expression  of class  II mRNA  in  the  class  II-deficient pa- 
tients  KER. and KEN suggested that they represent  a  new 
phenotype of MHC class II CID. Previously identified class 
II-negative cell lines, both patient derived and experimen- 
tally generated,  have been placed into four complementa- 
tion groups by somatic cell fusion analysis, implying that at 
least  four separate  genetic  lesions  can lead to  the  class  II- 
negative  phenotype.  We  extended  that  type  of genetic 
analysis to KER and KEN and showed that they define  a 
new CID complementation group and presumably represent 
Figure  3.  Lack of expression of 
DMA and DMB in group V CID 
cell lines. Northern blot analysis of 
expression of the  DMA  (top) and 
DMB  (bottom)  genes in KER, KEN, 
and in EBV-transformed  B-LCL  de- 
rived  from  the  patient's parents 
(Mother,  Father). 
a  mutation in another  gene  critical for class  II antigen ex- 
pression. KER. and KEN also exhibit a mixed pattern of in 
vivo MHC class II promoter occupancy that correlates com- 
pletely with the transcriptional status of the various class II 
genes:  those  genes  that  are  transcribed  (Dkc~,  DQot,  and 
DP[3)  have  an  occupied  promoter,  whereas  those  genes 
that  are  transcriptionally  silent  (DR[3,  DQ[3,  and  DPcx) 
have  bare  promoters.  This  dyscoordinate  regulation  be- 
tween  the  ix  and  [3  chains  of a  given  HLA isotype  is  the 
hallmark of complementaion group V. 
There  are numerous examples of cell lines,  both normal 
and malignant, that show a dissociation of expression among 
the three class II isotypes. A derivative of the Burkitt's lym- 
phoma Jijoye, clone 13, for example, expresses DQ but not 
DR  and DP  (33).  In human  dermal  fibroblasts,  treatment 
with  IFN-~/ induces  detectable  DR  and DP but  not DQ 
(34). Malignant B  cells  have been described that fail to ex- 
press  one or more specific class  II isotypes (35,  36).  These 
studies,  taken  together,  suggest  that  certain  class  II  genes 
may be  regulated  differentially  at  the  transcriptional  level. 
None  of these  examples,  however,  reflect  the  pattern  of 
dyscoordinate regulation seen in KER and KEN: the tran- 
scription of a given MA chain but not the [3 chain (or vice 
versa) for a specific HLA-D isotype. 
Analysis of cell lines from the four previously described 
CID  complementation  groups  by  in  vivo  genomic  foot- 
printing  has  suggested  two  different  mechanisms  for  the 
lack  of transcription  of class  II  genes  (25,  27).  The  bare 
promoter phenotype points to a defect in promoter accessi- 
bility since factors recognizing some or all of the promoter 
elements conserved among class II genes can be detected in 
vitro.  The occupied promoter phenotype suggests a defect 
in an activation domain of either a promoter-binding pro- 
tein or a protein that interacts with promoter-binding fac- 
tors.  Indeed,  CIITA, the  gene  defective in complementa- 
tion  group  II,  does  not  itself bind  DNA  but  appears  to 
function  as  a  coactivator  (15).  In  cells  of the  B  lineage, 
where the expression of MHC  class  II antigens is develop- 
mentally regulated,  the occupied promoter phenotype cor- 
relates with transcriptionally active class II genes, as in mature 
B  cells,  whereas  the bare  promoter phenotype is  observed 
in pre-B cells and in plasma cells,  where the class  II genes 
are  transcriptionally  silent  (37).  These  results  imply  that 
promoter  accessibility  is  a  primary  determinant  of class  II 
expression and that such accessibility may be developmen- 
tally regulated. 
The dyscoordinate regulation of the class II genes as well 
as  the  mixed  pattern  of promoter  occupancy observed  in 
KEN and KER suggest that the defect in complementation 
group V may have unmasked a previously unrecognized level 
of  regulation of  the MHC class II genes. Of the many factors 
known to bind to the highly conserved W, X1, X2, and Y 
elements  common to all  class  II promoters,  not alI factors 
bind with equal affinity to all promoters. One of these fac- 
tors,  RFX,  shows a  distinct  hierarchy of binding to the ix 
chain promoters: a high affinity for DRix, a reduced affinity 
for DPcx,  and a  very low  affinity for DQix.  Furthermore, 
binding of RFX to the [3 chain promoters is weak or non- 
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Figure  4.  Transcriptional orientation  of  genes 
within the MHC class II region. Leftward- or right- 
ward-pointing  arrows indicate the  direction  of tran- 
scription of the HLA-DI~,  -DP,  and -DQ ~x and 
genes as well as the DMA and DMB genes. 
existent  (38,  39).  Another  factor that  binds  to  the  X  box 
motif, X2BP,  shows a completely different pattern  of pro- 
moter-binding  affinities  with  DP[3  >DRcx  >DRI3, 
whereas  no binding is seen  to DQot,  DQJ3,  or DPtx  (40). 
Finally,  hXBP1  binds  only to  the  X2  boxes  of the  DR[3 
and  DP[3  promoters  (41).  These  studies  suggest  that  the 
combination of factors necessary to achieve coordinate reg- 
ulation of the six class II ot and MA chain genes may in fact 
differ from gene to gene. Thus, it is possible that the dysco- 
ordinate  regulation  of the  class  II genes  in  complementa- 
tion group V  might be due to a mutational inactivation of a 
promoter-binding  factor  required  for  the  expression  of 
DRJ3, DQJ3, and DPe~, but not for DRot, DQet, and DP[3. 
None of the factors described to date, however, fit this par- 
ticular pattern of binding affinities. 
Another  explanation  for the pattern  of class II gene ex- 
pression in group V  is suggested by the striking fact that all 
of the  transcriptionally  active  class  II genes  in  KEN  and 
KER share  the same transcriptional  orientation  within  the 
MHC  class II locus.  Conversely, those genes that are tran- 
scriptionally silent share the  opposite transcriptional  orien- 
tation.  Thus,  DRa,  DQot,  and  DPI3  are  transcribed  from 
right to left, whereas DR[3,  DQ[3, DPo~ are all transcribed 
from left to right,  as diagrammed in  Fig.  4.  In addition  to 
the defect in the transcription of certain class II genes, KER 
and KEN also fail to express DMA and DMB, genes whose 
promoters are quite homologous to the those of the class II 
structural genes and are thought to share a common regula- 
tory mechanism  (29,  30,  42).  The orientation  of these two 
nontranscribed  genes  within  the  HLA-D  region  of the 
MHC  is  the  same as  those  class  II genes  not  expressed  in 
KER  and  KEN;  that  is,  they  are  transcribed  from left  to 
right.  It  seems  unlikely  that  the  lack  of transcription  of 
DR[3, DQ[3, DPc~, DMA, and DMB could result from in- 
dividual mutations in the promoters of these genes. Rather, 
this global lack of transcription  is more reminiscent  of the 
effects of a  locus  control  region,  albeit  one  that  exerts  its 
effects  directionally  on  class  II-like  promoters.  To  our 
knowledge, no example of such a unidirectional locus con- 
trol region has been reported. 
The defect in group V  CID, in addition  to its effects on 
isotype-specific  dysregulation,  may also play a  role  in  cell 
type--specific  expression  of the  class  II  genes.  Although, 
there  is no  class  II protein detectable  on the  surface of ei- 
ther primary or EBV-transformed  B-LCL from KER  and 
KEN,  the  fact that they have normal levels of CD4 +  cells 
suggests that these patients must express class II antigens in 
the  thymus  (43).  Furthermore,  since both patients are able 
to mount specific antibody responses, some class II must be 
expressed in the periphery (16). Indeed, we have suggested 
that  there  may be  HLA-DR  present  on  certain  adherent 
monocyte populations  at levels too low to be detected  by 
flow  cytometry based  on  the  finding  of apparently  intact 
intracellular DRot and DR[3 in these cells (17). This would 
suggest that the  regulation  of the  class  II genes  in B  cells, 
thymic  epithelial  cells,  and  macrophages  may  differ.  Fur- 
ther,  such  cell  type-specific  transcriptional  differences 
might also be attributable  to the effects of the gene defec- 
tive in group V  CID. 
Identification  of the gene(s) responsible for the dyscoor- 
dinate  regulation  and  the  differences  in  tissue-specific  ex- 
pression  of the  MHC  class II genes in  group V  CID may 
provide insight into the aberrant expression of class II anti- 
gens in certain autoimmune diseases.  The ability to manip- 
ulate the immune system by regulating patterns  of expres- 
sion of class  II in an isotype- and cell type--specific manner 
suggests more gently tuned  immunomodulatory  treatment 
options than those currendy available. 
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